Veterinary Pain Management Market - By Product (Drug [NSAID, Opioid], Device [Laser, Electromagnetic]), By Application (Joint Pain, Cancer, Postoperative), By Animal (Companion, Livestock), By End-user (Hospital, Clinic) & Global Forecast, 2024-2032

Veterinary Pain Management Market Size

Veterinary Pain Management Market size was estimated to be USD 1.7 billion in 2023 and is expected to expand at a CAGR of 7.1% by 2032. The rising number of pet owners, increasing prevalence of animal diseases, increasing animal medicalization rate, increasing adoption of pet insurance, and rising adoption of laser therapy in pain management are some of the key factors driving this market.
 

Pain management in veterinary practice provides veterinary practitioners with the information needed to recognize and manage pain in a wide range of large, small, and exotic animal species. Numerous conditions, including arthritis, cancer, surgical procedures can cause pain and the treatment options include laser therapy, prescription drugs, therapeutic massages, complementary therapies, and electromagnetic therapy.
 

Additionally, rising preventive care and treatment facilities for companion animals, increased acceptance of unconventional and non-pharmaceutical treatment modalities, increasing adoption of veterinary services and rising animal healthcare spending will all contribute to a growth of animal drugs market including pain management therapeutics.
 

Covid-19 Impact

The COVID-19 pandemic had an adverse impact on the veterinary pain management market, especially in 2020. This negative impact was mainly due to lockdown in various countries, which led to closures and restrictions on access to veterinary care. This fact has created barriers for pets to access veterinary services for their beloved companions due to the shutdown and forced closure of veterinary hospitals and clinics. In addition, veterinary hospitals, and clinics faced major challenges during the pandemic due to the risk of disease transmission in facilities and native habitats.
 

Pet owners are also encouraged to keep a safe distance from their animals to ensure hygiene and reduce the risk of contamination. The livestock sector and its related industries are among the most impacted sectors. This is mainly ascribed to the limitations of animal movement and the decrease of production inputs' availability. On the other hand, the increased adoption rate of pets during the lockdown increased the demand for veterinary products including pain management drugs.
 

Post pandemic, the market has started to gain momentum and is expected to maintain an upward trend over the forecast period. Factors such as increasing pet population, increasing animal health expenditure, and development in adoption of pet insurance are expected to fuel the market expansion.
 

Veterinary Pain Management Market Trends

Veterinary pain management refers to a medical approach toward the prevention, diagnosis, and treatment of pain caused by several factors, such as physical trauma, internal organ problems, surgical procedures, and spine problems, arthritis, and joint damage. 
 

Growing incidences of infectious diseases and increased awareness and diagnosis about deficiency diseases, hereditary diseases, and physiological diseases in animals all around the globe is one of the major factors fostering the growth of the market. The relationship of pet owners with their pets can absolutely have an impact on veterinary care and the animal’s quality of life. The increasing adoption of pets along with growing awareness about pet’s health is expected to increase the adoption of veterinary medicine.
 

Surging focus on improving the condition of veterinary facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities. Also, rising government initiatives to increase awareness about importance of early diagnosis is yet again bolstering the market escalation rate.
 

Veterinary Pain Management Market Analysis

Based on product, the veterinary pain management market is segmented into drugs and devices. Drugs segment accounted for the largest market share in terms of revenue in 2022. .  The veterinary pain management drugs are more widely used and cost-effective. Drugs are able to treat a wide variety of diseases and are more easily available, and also, they are convenient to administer in certain scenarios compared to devices. The drugs are further subsegmented into NSAIDS, opioids, anesthetics, alpha-2 agonists, and other drugs.
 

Companies are trying to develop new NSAIDs with lesser adverse effects and reactions. For instance, in January 2022, the U.S. FDA approved Zorbium (buprenorphine transdermal solution), the first transdermal buprenorphine animal medication for post-surgical pain management in cats.
 

By application, the veterinary pain management market is segmented into joint pain, cancer, postoperative pain, and other applications. The joint pain segment accounted for the largest market share in 2022. The large share of this segment can be attributed to increasing prevalence of animal diseases includes osteoarthritis and musculoskeletal disorders. For instance, in 2021, as per the report published by journal of small animal practices, 1 in 5 dogs (20%) experience hip & joint issues at some point in their life. This can result in pain, reduction in mobility and a possible reduction in a dog’s quality of life. Trying to determine dog joint pain or dog mobility issues can be a stressful task for pet parents, which is expected to boost the market upsurge.
 

Based on animal type, the veterinary pain management market is segmented into companion animals and livestock animals. The companion animal segment accounted for the largest revenue share in 2022 owing to increase in their ownership, awareness regarding better pet care, demand for efficient animal care, and high animal healthcare spending in developing countries.
 

By end-user, the market is segmented into veterinary hospitals, veterinary clinics, retail pharmacies, and online pharmacies. The veterinary hospitals segment dominated the market and accounted for the largest market share of 43.8% in 2022. This is owing to a growing number of veterinary hospitals globally with advanced infrastructures.
 

Veterinary hospitals are very crucial for veterinary pain management as they provide professional therapies.
 

Veterinary Pain Management Market Share

The key veterinary pain management market players include

• Boehringer Ingelheim International GmbH
• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Incorporated
• Norbrook
• Ceva Santé Animale
• Dechra Pharmaceuticals
• Vetoquinol Inc
•  Alivira Animal Health Limited
• Chanelle Pharma
• K-Laser USA
• Multi Radiance Medical
   

Market players adopt and implement various strategies, such as product launches, collaborations, expansions, and mergers. For instance, in October 2021, Summus Laser introduced “Horizon Veterinary Laser System,’’ a Class IV laser therapy system designed specifically for veterinary pain management. It is a diode-based laser with 28-watt power and has the unique capability of combining four different wavelengths, which can be controlled independently as well.
 

Veterinary Pain Management Regional Segmentation

North America is expected to dominate the overall veterinary pain management market over the forecast period. The growth is due to factors such as rising pet adoption, increasing adoption of pet insurance, increasing awareness about pet’s health among pet owners, and the increasing animal healthcare expenditure in the region. The rise in the prevalence of various animal diseases and injuries has been identified as the major factor fuelling the market's rise.
 

Veterinary pain management market news:

• In September 2022, Zoetis launched Solensia to manage feline osteoarthritis pain in the United States.
   
• In April 2022, The U.S. FDA has approved medetomidine and vatinoxan hydrochlorides injection (Zenalpha) for use as a sedative and analgesic in dogs, while undergoing certain clinical examination and procedures, and minor surgical procedures.
   
• In January 2018, Dechra Pharmaceuticals acquired Le Vet and Ast Farma in a probe to expand its business in the Netherlands and Europe. this partnership was focused on launch of new product, Tralieve (a pain relief tablet), in Germany, the UK, and France.
   

The veterinary pain management market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product

• Drugs
• Drug type
  • NSAIDS
  • Opioids
  • Anesthetics
  • Alpha-2 agonists
  • Other drugs
• Route of administration
  • Oral
  • Parenteral
  • Topical 
• Devices
• Laser therapy
• Electromagnetic therapy

By Application

• Joint Pain
• Osteoarthritis
• Musculoskeletal disorders 
• Cancer
• Postoperative pain
• Other applications

By Animal Type

• Companion animals
• Dogs
• Cats
• Horses
• Other companion animals

• Livestock animals
• Cattel
• Swine
• Other livestock animals

By End-user

• Veterinary hospitals
• Veterinary clinics
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe          
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific   
• Latin America       
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa        
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa